News | Quality Assurance (QA) | July 08, 2019

PTW to Feature New Dosimetry Technology at AAPM 2019

Offerings will include new water phantom for MR-guided radiotherapy, modular patient and machine QA systems

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

July 8, 2019 — At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will exhibit its full range of dosimetry solutions for magnetic resonance-guided radiotherapy (MRgRT), beam data commissioning and stereotactic quality assurance (QA).

PTW will exhibit and demonstrate its latest technology and most recent product developments including:

  • Beamscan MR 3-D water phantom – The first 3-D water phantom for MR-guided radiotherapy, according to the company, available in two models for Elekta Unity and ViewRay MRIdian. Beamscan MR 3-D is pending U.S. Food and Drug Administration (FDA) 510(k) clearance and is not available for sale in the U.S.;
  • Beamscan 3-D water phantom – Fast to set up and easy to use for all acceptance testing and commissioning needs, now available for the Halcyon system;
  • Octavius 4-D modular patient and machine QA systems – For the latest radiotherapy techniques, including Halcyon, stereotactic radiosurgery (SRS) and MRgRT. Also introducing Octavius Detector 1600 SRS for 3-D dose verification of complex SRS/SBRT (stereotactic body radiation therapy) treatment plans;
  • Ruby phantom – A new modular stereotactic verification phantom with multiple inserts for comprehensive system QA, linear accelerator (linac) QA and patient QA:
  • StarCheck arrays – High-resolution ionization chamber arrays for comprehensive, TG-142-compliant linac QA, available in three models for standard (25 x 25 cm²), large (40 x 40 cm²) and magnetic fields;
  • microSilicon diode detector – The new silicon diode detector for small photon and all electron fields; and
  • Track-it 2.0 QA data management software – Versatile, web-based QA data management software that integrates QA data from different sources, devices and sites into a single platform.

PTW is hosting a Lunch and Learn symposium for AAPM attendees on Monday, July 15. The event will feature the following presenters:

  • Jochem Wolthaus, Ph.D., a medical physicist at the University Medical Center Utrecht, will present “The Development and Experience of the first MR-compatible 3-D Scanning Water Tank for Acceptance, Commissioning and QA measurements in an MRI-LINAC”; 
  • Dan Nicewonger, a medical physicist at the MD Anderson Cancer Center in San Antonio, will present “QA Data Flow in Modern Radiotherapy Departments”; and
  • Sharon Thompson, a medical physicist from the Maimonides Cancer Center, Brooklyn, N.Y., will present “Challenges of Beam Data Collection and Validation of Halcyon during Commissioning.”

For more information: www.ptwdosimetry.com

Related Content

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
"Our study demonstrates that a real-world lung cancer screening can perform similar to randomized controlled trials in regard to important performance metrics," the UPenn authors of this AJR article concluded. Image courtesy of American Journal of Roentgenology (AJR)

"Our study demonstrates that a real-world lung cancer screening can perform similar to randomized controlled trials in regard to important performance metrics," the UPenn authors of this AJR article concluded. Image courtesy of American Journal of Roentgenology (AJR)

News | Lung Imaging | July 17, 2020
July 17, 2020 — An online first accepted...
PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in keeping with the known tumor recurrence in the prostate. Right: PET shows extensive, intensely PSMA-avid local recurrence in prostate (top row; solid arrow) and a solitary bone metastasis in left rib 2 (bottom row; dotted arrow). Image courtesy of Ur Metser, et al.

PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in keeping with the known tumor recurrence in the prostate. Right: PET shows extensive, intensely PSMA-avid local recurrence in prostate (top row; solid arrow) and a solitary bone metastasis in left rib 2 (bottom row; dotted arrow). Image courtesy of Ur Metser, et al.

News | PET-CT | July 16, 2020
July 16, 2020 — New research confirms the high impact of...
Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared to a typical clinical standardized uptake value image (b), the parametric image of FDG influx rate (Ki) can achieve higher lesion-to-background (e.g., the liver) contrast. In addition to glucose metabolism imaging by Ki, total-body dynamic PET also enables multiparametric characterization of tumors and organs

Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared to a typical clinical standardized uptake value image (b), the parametric image of FDG influx rate (Ki) can achieve higher lesion-to-background (e.g., the liver) contrast. In addition to glucose metabolism imaging by Ki, total-body dynamic PET also enables multiparametric characterization of tumors and organs using additional physiologically important parameters, for example, glucose transport rate K1 (d), across the entire body. Image courtesy of G.B. Wang, M. Parikh, L. Nardo, et al., University of California Davis, Calif.

News | PET Imaging | July 16, 2020
July 16, 2020 — Results from the first...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Simulation finds starting at age 30 with MRI and mammography to be the preferred strategy; starting at 25 prevented marginally more deaths, but with more testing and emotional stress

Getty Images

News | Breast Imaging | July 09, 2020
July 9, 2020 — Chest radiation is used to treat children with Hodgkin and non-Hodgkin lymphoma as well as lung metast
At the American Association of Physicists in Medicine (AAPM) 2019 meeting, new artificial intelligence (AI) software to assist with radiotherapy treatment planning systems was highlighted. The goal of the AI-based systems is to save staff time, while still allowing clinicians to do the final patient review. 
Feature | Treatment Planning | July 08, 2020 | By Melinda Taschetta-Millane
At the American Association of Physicists in Medicine (AAPM) 201
Changes outlined in new draft U.S. Preventive Services Task Force (USPSTF) lung cancer screening recommendations will greatly increase the number of Americans eligible for screening and help medical providers save thousands more lives each year.

Image courtesy of Cerner

News | Lung Imaging | July 08, 2020
July 8, 2020 — Changes outlined in new draft U.S.